Flufenamic acid
Flufenamic acid is a member of the anthranilic acid derivatives class of NSAID drugs Like other members of the class, it is a COX inhibitor and prevents formation of prostaglandins. FFA is known to bind to and reduce the activity of prostaglandin F synthase and activate TRPC6.
It is not widely used in humans as it has a high rate of gastrointestinal side effects. It is generally not available in the US. It is available in some Asian and European countries as a generic.
Scientists led by Claude Winder from Parke-Davis invented FFA in 1963, along with fellow members of the class, mefenamic acid in 1961 and meclofenamate sodium in 1964.
